Cagrilintide
Also called AM833.
Cagrilintide is still investigational, with no FDA-approved product. This page cites 3 sources, and the strongest evidence comes from human trials.
- Status
- Investigational
- Form
- Injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 2
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
Once-weekly subcutaneous cagrilintide monotherapy produced greater weight loss than placebo after 26 weeks in adults without diabetes who had obesity, or overweight with hypertension or dyslipidemia.
Limits: The 706-participant phase 2 study compared several cagrilintide groups, liraglutide, and placebo. Gastrointestinal events and injection-site reactions occurred. Short-term results do not establish long-term clinical outcomes or the safety of other preparations.
Human trials
A post hoc analysis of REDEFINE 1 reported greater weight loss with cagrilintide alone than placebo after 68 weeks in adults with obesity or overweight with a complication, without diabetes.
Limits: Novo Nordisk reported treatment-policy estimates of 11.5% versus 3.0%. This secondary analysis is distinct from the CagriSema combination result and does not establish cardiovascular benefit or regulatory approval.
Regulatory status
United States
Investigational and not FDA-approved for any indication as of November 6, 2026. FDA identifies cagrilintide as not a component of an approved drug.